title: [Peripheral nervous system neurotoxicity secondary to chemotherapy treatment]  .
abstract: Peripheral neurotoxicity is a crucial side effect of chemotherapeutic agents. It is the only situation where there is no preventive treatment. Neuromuscular toxicity has become the major dose limiting side effect for many chemotherapeutic agents. The iatrogenic toxic neuropathy is a growing neurologic problem, as cancer patients are beign treated with increasing doses of chemotherapy drugs. Major advances in cancer treatment have resulted from the use of drug combinations; for some combinations this raises the possibility of sinergistic neurotoxicity. The following report reviews the SNP toxicities encountered with cisplatin, vincristine, taxanes and others, and methods to minimize the deleterious effect of chemotherapeutic agents.
authors.affiliation: Servicio de Neurología, Hospital Clínico Universitario, Juan Bosco, 15, 50009 Zaragoza. ciniguezm@nacom.es
authors.forename: C
authors.initials: C
authors.lastname: Iñiguez
authors.forename: P
authors.initials: P
authors.lastname: Larrodé
authors.forename: J I
authors.initials: JI
authors.lastname: Mayordomo
authors.forename: J A
authors.initials: JA
authors.lastname: Mauri
authors.forename: A
authors.initials: A
authors.lastname: Trés
authors.forename: F
authors.initials: F
authors.lastname: Morales
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects; D047630:Depsipeptides; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009468:Neuromuscular Diseases / Q000139:chemically induced* / Q000628:therapy; D009842:Oligopeptides / Q000009:adverse effects; D009944:Organoplatinum Compounds / Q000009:adverse effects; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000628:therapy; D011344:Procarbazine / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D013498:Suramin / Q000009:adverse effects; D043823:Taxoids; D014748:Vinca Alkaloids / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D047630:Depsipeptides; D009842:Oligopeptides; D009944:Organoplatinum Compounds; D018894:Reverse Transcriptase Inhibitors; D043823:Taxoids; D014748:Vinca Alkaloids; D000077143:Docetaxel; D011344:Procarbazine; D013498:Suramin; D004317:Doxorubicin; D016572:Cyclosporine; C064570:dolastatin 10; D017239:Paclitaxel